Man Group plc Buys 4,384 Shares of Becton, Dickinson and Company $BDX

Man Group plc increased its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 30.9% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 18,549 shares of the medical instruments supplier’s stock after buying an additional 4,384 shares during the period. Man Group plc’s holdings in Becton, Dickinson and Company were worth $2,807,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently made changes to their positions in the company. Imprint Wealth LLC acquired a new stake in Becton, Dickinson and Company during the 3rd quarter worth approximately $25,000. SHP Wealth Management acquired a new stake in shares of Becton, Dickinson and Company during the fourth quarter worth $26,000. Meeder Asset Management Inc. grew its stake in shares of Becton, Dickinson and Company by 152.2% in the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock valued at $27,000 after acquiring an additional 102 shares in the last quarter. Main Street Group LTD bought a new position in Becton, Dickinson and Company during the first quarter worth about $29,000. Finally, Bell Investment Advisors Inc bought a new stake in Becton, Dickinson and Company in the 2nd quarter valued at about $29,000. Institutional investors own 86.97% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. The Goldman Sachs Group cut their price target on Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating for the company in a research note on Wednesday, May 27th. Bank of America lifted their price objective on Becton, Dickinson and Company from $185.00 to $200.00 and gave the company a “neutral” rating in a report on Monday. Stifel Nicolaus set a $195.00 target price on Becton, Dickinson and Company in a research report on Friday, August 7th. Barclays raised their price target on Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Becton, Dickinson and Company in a research note on Friday, August 7th. Eight analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $187.67.

Becton, Dickinson and Company Trading Down 0.7%

Shares of BDX stock opened at $188.13 on Tuesday. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $193.07. The stock’s fifty day moving average price is $167.10 and its two-hundred day moving average price is $160.32. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87. The company has a market cap of $51.84 billion, a PE ratio of 56.67, a P/E/G ratio of 13.36 and a beta of 0.19.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, topping the consensus estimate of $3.14 by $0.09. The business had revenue of $4.98 billion during the quarter, compared to the consensus estimate of $4.89 billion. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.During the same period in the prior year, the company earned $3.68 EPS. Becton, Dickinson and Company’s revenue for the quarter was up 5.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Equities analysts predict that Becton, Dickinson and Company will post 12.67 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be issued a dividend of $1.05 per share. The ex-dividend date of this dividend is Wednesday, September 9th. This represents a $4.20 annualized dividend and a dividend yield of 2.2%. Becton, Dickinson and Company’s payout ratio is 126.51%.

Insider Activity at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 1,100 shares of the stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total value of $160,226.00. Following the completion of the transaction, the executive vice president owned 13,172 shares of the company’s stock, valued at $1,918,633.52. This represents a 7.71% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Feld sold 165 shares of the business’s stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total transaction of $31,100.85. Following the sale, the executive vice president directly owned 19,720 shares in the company, valued at approximately $3,717,022.80. The trade was a 0.83% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 9,105 shares of company stock valued at $1,590,208 in the last quarter. 0.40% of the stock is owned by company insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.